RU2017112747A - Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции - Google Patents
Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции Download PDFInfo
- Publication number
- RU2017112747A RU2017112747A RU2017112747A RU2017112747A RU2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A
- Authority
- RU
- Russia
- Prior art keywords
- quinidine
- treatment
- dementia
- dextrometorphanic
- demenium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Claims (8)
1. Способ лечения возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией, включающий введение нуждающемуся в этом пациенту дейтерированного декстрометорфана и хинидина.
2. Способ по п.1, в котором типом деменции является болезнь Альцгеймера.
3. Дейтерированный декстрометорфан и хинидин для применения в лечении возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией.
4. Дейтерированный декстрометорфан и хинидин по п.3, где типом деменции является болезнь Альцгеймера.
5. Применение дейтерированного декстрометорфана и хинидина для лечения возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией.
6. Применение по п.5, где типом деменции является болезнь Альцгеймера.
7. Применение дейтерированного декстрометорфана и хинидина для получения лекарственного средства для лечения возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией.
8. Применение по п.7, где типом деменции является болезнь Альцгеймера.
Applications Claiming Priority (35)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462050170P | 2014-09-14 | 2014-09-14 | |
US62/050,170 | 2014-09-14 | ||
US201462061451P | 2014-10-08 | 2014-10-08 | |
US62/061,451 | 2014-10-08 | ||
US201462063122P | 2014-10-13 | 2014-10-13 | |
US62/063,122 | 2014-10-13 | ||
US201462063861P | 2014-10-14 | 2014-10-14 | |
US62/063,861 | 2014-10-14 | ||
US201462068742P | 2014-10-26 | 2014-10-26 | |
US62/068,742 | 2014-10-26 | ||
US201562111053P | 2015-02-02 | 2015-02-02 | |
US62/111,053 | 2015-02-02 | ||
US201562111590P | 2015-02-03 | 2015-02-03 | |
US62/111,590 | 2015-02-03 | ||
US201562128446P | 2015-03-04 | 2015-03-04 | |
US62/128,446 | 2015-03-04 | ||
US201562162140P | 2015-05-15 | 2015-05-15 | |
US62/162,140 | 2015-05-15 | ||
US201562165535P | 2015-05-22 | 2015-05-22 | |
US62/165,535 | 2015-05-22 | ||
US201562169997P | 2015-06-02 | 2015-06-02 | |
US62/169,997 | 2015-06-02 | ||
US201562180026P | 2015-06-15 | 2015-06-15 | |
US62/180,026 | 2015-06-15 | ||
US201562193347P | 2015-07-16 | 2015-07-16 | |
US62/193,347 | 2015-07-16 | ||
US201562205061P | 2015-08-14 | 2015-08-14 | |
US62/205,061 | 2015-08-14 | ||
US201562216636P | 2015-09-10 | 2015-09-10 | |
US62/216,636 | 2015-09-10 | ||
US201562217470P | 2015-09-11 | 2015-09-11 | |
US201562217142P | 2015-09-11 | 2015-09-11 | |
US62/217,142 | 2015-09-11 | ||
US62/217,470 | 2015-09-11 | ||
PCT/US2015/049934 WO2016040930A1 (en) | 2014-09-14 | 2015-09-14 | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020116666A Division RU2020116666A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2017112747A true RU2017112747A (ru) | 2018-10-15 |
RU2017112747A3 RU2017112747A3 (ru) | 2019-04-29 |
Family
ID=55459653
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017112747A RU2017112747A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
RU2020116666A RU2020116666A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020116666A RU2020116666A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
Country Status (14)
Country | Link |
---|---|
US (3) | US20190111047A1 (ru) |
EP (4) | EP4166141A1 (ru) |
JP (4) | JP2017531033A (ru) |
KR (1) | KR20170052684A (ru) |
CN (3) | CN110664801A (ru) |
AU (3) | AU2015314710A1 (ru) |
CA (1) | CA2960031A1 (ru) |
IL (2) | IL250786A0 (ru) |
MX (3) | MX2017003066A (ru) |
PH (1) | PH12017500444A1 (ru) |
RU (2) | RU2017112747A (ru) |
SG (2) | SG11201701645WA (ru) |
TW (3) | TW202231278A (ru) |
WO (1) | WO2016040930A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017020014A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
CA2994169A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
ES2840078T3 (es) * | 2016-07-04 | 2021-07-06 | Avanir Pharmaceuticals Inc | Métodos para la síntesis de dextrometorfano deuterado |
US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
CN112424600B (zh) * | 2018-05-18 | 2023-10-10 | 阿纳韦克斯生命科学公司 | σ-1激动剂治疗的优化和受治疗者的筛选方法 |
MX2021008247A (es) * | 2019-01-07 | 2021-08-16 | Antecip Bioventures Ii Llc | Combinacion de dextrometorfano y bupropion para el tratamiento de depresion. |
AU2020241611A1 (en) * | 2019-03-18 | 2021-11-04 | Avanir Pharmaceuticals, Inc. | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine |
BR112022021535A2 (pt) * | 2020-04-27 | 2023-01-24 | Avanir Pharmaceuticals Inc | Métodos para tratar agitação associada ao mal de alzheimer |
WO2022228363A1 (zh) * | 2021-04-27 | 2022-11-03 | 杭州剂泰医药科技有限责任公司 | 一种组合物的医药用途 |
CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
WO2023076414A1 (en) * | 2021-10-27 | 2023-05-04 | Avanir Pharmaceuticals, Inc. | Methods of treating agitation associated with alzheimer's disease |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
TW264473B (ru) * | 1993-01-06 | 1995-12-01 | Hoffmann La Roche | |
US5863927A (en) | 1994-09-22 | 1999-01-26 | Center For Neurologic Study | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
IL136044A (en) | 1997-11-21 | 2005-08-31 | Euro Celtique Sa | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same |
WO1999050245A1 (fr) | 1998-03-26 | 1999-10-07 | Shionogi & Co., Ltd. | Derives d'indole exerçant une activite antivirale |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
MX2008009947A (es) * | 2006-02-03 | 2008-10-20 | Avanir Pharmaceuticals | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. |
US20070224128A1 (en) * | 2006-03-07 | 2007-09-27 | Donn Michael Dennis | Drug adherence monitoring system |
WO2008097924A2 (en) * | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
CA2809739C (en) | 2007-05-01 | 2016-11-15 | Concert Pharmaceuticals Inc. | Morphinan compounds |
EP2334678B1 (en) * | 2008-09-19 | 2012-12-26 | Concert Pharmaceuticals Inc. | Morphinan compounds |
PL2397158T3 (pl) * | 2008-10-30 | 2016-09-30 | Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu | |
CA2743902C (en) * | 2008-11-14 | 2016-09-20 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
KR102264179B1 (ko) * | 2013-11-05 | 2021-06-11 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법 |
-
2015
- 2015-09-14 TW TW110139834A patent/TW202231278A/zh unknown
- 2015-09-14 TW TW109114123A patent/TW202106301A/zh unknown
- 2015-09-14 MX MX2017003066A patent/MX2017003066A/es unknown
- 2015-09-14 US US15/510,498 patent/US20190111047A1/en not_active Abandoned
- 2015-09-14 KR KR1020177009991A patent/KR20170052684A/ko not_active Application Discontinuation
- 2015-09-14 SG SG11201701645WA patent/SG11201701645WA/en unknown
- 2015-09-14 AU AU2015314710A patent/AU2015314710A1/en not_active Abandoned
- 2015-09-14 EP EP22195837.4A patent/EP4166141A1/en active Pending
- 2015-09-14 CN CN201910903770.XA patent/CN110664801A/zh active Pending
- 2015-09-14 SG SG10201901242PA patent/SG10201901242PA/en unknown
- 2015-09-14 CN CN202311175974.9A patent/CN117427077A/zh active Pending
- 2015-09-14 CA CA2960031A patent/CA2960031A1/en active Pending
- 2015-09-14 WO PCT/US2015/049934 patent/WO2016040930A1/en active Application Filing
- 2015-09-14 EP EP15840718.9A patent/EP3193872A4/en not_active Withdrawn
- 2015-09-14 TW TW104130311A patent/TW201613591A/zh unknown
- 2015-09-14 RU RU2017112747A patent/RU2017112747A/ru not_active Application Discontinuation
- 2015-09-14 EP EP21178170.3A patent/EP3932907A3/en not_active Withdrawn
- 2015-09-14 EP EP20159783.8A patent/EP3708168A3/en not_active Withdrawn
- 2015-09-14 JP JP2017533726A patent/JP2017531033A/ja active Pending
- 2015-09-14 CN CN201580049454.0A patent/CN107072990A/zh active Pending
- 2015-09-14 RU RU2020116666A patent/RU2020116666A/ru unknown
-
2017
- 2017-02-26 IL IL250786A patent/IL250786A0/en unknown
- 2017-03-08 MX MX2022008181A patent/MX2022008181A/es unknown
- 2017-03-08 MX MX2021010696A patent/MX2021010696A/es unknown
- 2017-03-09 PH PH12017500444A patent/PH12017500444A1/en unknown
-
2019
- 2019-10-08 US US16/596,236 patent/US20200289499A1/en not_active Abandoned
- 2019-11-06 JP JP2019201410A patent/JP2020019818A/ja not_active Withdrawn
-
2020
- 2020-05-18 IL IL274742A patent/IL274742A/en unknown
- 2020-12-15 AU AU2020289733A patent/AU2020289733A1/en not_active Abandoned
-
2021
- 2021-03-08 JP JP2021036318A patent/JP7360409B2/ja active Active
-
2022
- 2022-12-06 AU AU2022283671A patent/AU2022283671A1/en active Pending
-
2023
- 2023-04-24 US US18/305,589 patent/US20240082237A1/en active Pending
- 2023-06-12 JP JP2023096152A patent/JP2023105265A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
JP2017075173A5 (ru) | ||
MX2020008024A (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas. | |
EA201490774A1 (ru) | Новые производные оксазина и их применение при лечении заболевания | |
EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
EA201790088A1 (ru) | Ингибиторы syk | |
EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
RU2017105353A (ru) | Соединения | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
JP2015516419A5 (ru) | ||
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
EA201590687A1 (ru) | Лечение легкой и умеренной болезни альцгеймера | |
EA201591021A1 (ru) | 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний | |
RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
RU2015131803A (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
RU2018110031A (ru) | Способ лечения и профилактика гриппа | |
RU2015153071A (ru) | Применение гептапептида бета-казоморфина-7 для коррекции симптомов болезни альцгеймера |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200730 |